arrett's esophagus (BE) is the only known precursor of esophageal adenocarcinoma. BE is believed to progress through dysplasia before developing into esophageal adenocarcinoma. Histologic evidence of dysplasia is the only widely used biomarker for predicting neoplastic progression. Management of BE with low-grade dysplasia (LGD) is challenging because of poor interobserver variability among pathologists for the diagnosis, and heterogeneous rates of neoplastic progression reported from various cohorts. In addition, endoscopists inexperienced in managing dysplasia might not recognize endoscopic lesions of early neoplasia, accentuating the propensity of sampling error in patients found to have LGD but actually harboring high-grade dysplasia (HGD) or early cancer in other areas of the esophagus. We therefore hypothesized that the observed progression rate to HGD or cancer within the first year after diagnosis of BE with LGD would be greater than the overall annual progression rate. If so, it would suggest that surveillance in the first year after diagnosis should be more frequent than subsequently.
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Methods
We conducted a systematic review in MEDLINE, EMBASE, and the Cochrane Library from 1980 to January 2016 to identify publications that reported both the overall annual incidence of HGD or cancer in patients with BE LGD and also reported the progression within the first year after diagnosis of BE LGD. The search strategy in MEDLINE was as follows: ((Barrett Esophagus or barrett*) or (esophagus and (metaplasia or intestine metaplasia or (intestine* adj2 metaplasia))) and ((early diagnosis or precancerous conditions or (precancer or dysplasia) or (lgd or ((low grade adj3 dysplas*) or (no dysplas* pre? neoplas* or pre?cancer*)). Similar queries were performed in the other databases. Non-English studies and studies that reported subjects in duplicate to another study were excluded.
The primary outcome was the median incidence rate ratio from a hierarchical Poisson meta-analysis that accounted for heterogeneity between studies and the correlation between the 2 rates within studies. In addition, meta-analyses estimated the rates of progression from LGD to either HGD or cancer during the first year, and annual rates of progression through the entire duration of followup evaluation, each using a random-effects model. Heterogeneity across the studies was estimated using the inconsistency index (I 2 ), in which less than 25% is considered low heterogeneity and greater than 75% is considered high heterogeneity, and P less than .05 indicates statistically significant heterogeneity. Analyses were performed in Stata v. 14 (StatCorp, College Station, TX).
Results
The initial queries identified 1492 articles. After an initial review of titles and abstracts, 126 articles were obtained for review. Of those, 13 studies excluded cases that progressed within the first year and did not provide the number of such subjects. A total of 8 studies were eligible (including reporting such data) and were included in the meta-analyses (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] The weighted summary annual incidence of the entire follow-up period from LGD to either HGD or cancer was 4.6 per 100 patient-years (95% CI, 2.0-7.2) with moderate heterogeneity (I 2 ¼ 51%; P ¼ .04 for test of heterogeneity). The weighted summary first year rate of progression was 8.8 per 100 patients (95% CI, 3.7-13.8) with high heterogeneity (I 2 ¼ 77%; P < .01). The median incident rate ratio for the first year vs overall progression rates was 2.34, indicating that, accounting for between-study heterogeneity, the incidence in the first year was approximately twice the overall annual progression rate. 
Discussion
We conducted a systematic review and series of metaanalyses and found that the incidence of HGD or cancer within the first year after diagnosis of LGD is approximately twice the annual incidence throughout follow-up evaluation. Most guidelines have recommended shorter intervals in the first year after diagnosis of LGD than subsequently, but based on expert opinion rather than empiric evidence. Our results confirm that the opinions of the experts in these guidelines are justified.
It is biologically implausible that the greater earlier yield represents true progression, but rather likely reflects misclassification of HGD or cancer as LGD as a result of sampling error or pathologist interpretation. For understanding the natural history of true LGD, many studies have excluded early progressors with the intent of avoiding misclassification. But for the purposes of clinical management of newly diagnosed BE LGD, the provider does not have foreknowledge regarding any misclassification. Relying on studies that exclude early progressors therefore overlooks the potential for misclassification and the potential benefit of early repeat endoscopy to evaluate for missed lesions. We found that the summary estimate of the first year rate of progression from LGD to HGD or cancer was 8.8%, a rate that we find substantial enough to warrant more frequent surveillance than in subsequent years.
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